Understanding Chemotherapy Responses in Triple-Negative Breast Cancer
Author Information
Author(s): Lei Jonathan T., Dobrolecki Lacey E., Huang Chen, Srinivasan Ramakrishnan R., Vasaikar Suhas V., Lewis Alaina N., Sallas Christina, Zhao Na, Cao Jin, Landua John D., Moon Chang In, Liao Yuxing, Hilsenbeck Susan G., Osborne C. Kent, Rimawi Mothaffar F., Ellis Matthew J., Petrosyan Varduhi, Wen Bo, Li Kai, Saltzman Alexander B., Jain Antrix, Malovannaya Anna, Wulf Gerburg M., Marangoni Elisabetta, Li Shunqiang, Kraushaar Daniel C., Wang Tao, Damodaran Senthil, Zheng Xiaofeng, Meric-Bernstam Funda, Echeverria Gloria V., Anurag Meenakshi, Chen Xi, Welm Bryan E., Welm Alana L., Zhang Bing, Lewis Michael T.
Primary Institution: Cold Spring Harbor Laboratory
Hypothesis
Can patient-derived xenografts help predict chemotherapy responses in triple-negative breast cancer?
Conclusion
The study found that combination chemotherapy is often no more effective than the best single agent in treating triple-negative breast cancer.
Supporting Evidence
- Combination chemotherapy often does not improve outcomes compared to the best single agent.
- Only about 13% of patient-derived xenografts showed enhanced response to combination therapy.
- Single-omic comparisons revealed non-overlapping results between single agent and combination treatments.
- High Cytokeratin-5 (KRT5) was identified as a marker of responsiveness.
- Integrating proteomic and transcriptomic data improved predictive modeling of treatment responses.
Takeaway
This study looked at how well different chemotherapy drugs work for breast cancer patients. It found that using two drugs together doesn't always work better than using just one.
Methodology
Multi-omic analyses of patient-derived xenografts treated with single and combination chemotherapy agents.
Limitations
The study may not fully capture all patient responses due to the complexity of individual cases.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website